Published in Cancer Res on January 01, 2008
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood (2010) 1.66
The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ (2009) 1.53
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood (2013) 1.35
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
Emerging Roles for SSeCKS/Gravin/AKAP12 in the Control of Cell Proliferation, Cancer Malignancy, and Barriergenesis. Genes Cancer (2010) 1.20
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer (2010) 1.16
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A (2014) 1.05
Ethnic diversity of DNA methylation in the OPRM1 promoter region in lymphocytes of heroin addicts. Hum Genet (2010) 1.00
Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12. Cancer Metastasis Rev (2012) 0.99
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther (2009) 0.98
piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma. Leukemia (2014) 0.98
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers (Basel) (2013) 0.97
Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer (2011) 0.97
Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. J Exp Clin Cancer Res (2010) 0.92
Identifying master regulators of cancer and their downstream targets by integrating genomic and epigenomic features. Pac Symp Biocomput (2013) 0.91
Epigenetics of drug abuse: predisposition or response. Pharmacogenomics (2012) 0.91
Cyclin K and cyclin D1b are oncogenic in myeloma cells. Mol Cancer (2010) 0.88
Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. Genome Med (2012) 0.88
Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. Carcinogenesis (2014) 0.87
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol (2011) 0.86
Re-expression of AKAP12 inhibits progression and metastasis potential of colorectal carcinoma in vivo and in vitro. PLoS One (2011) 0.86
Empowering biologists with multi-omics data: colorectal cancer as a paradigm. Bioinformatics (2014) 0.84
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene (2016) 0.83
DNA demethylation by 5-aza-2'-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences. Epigenetics Chromatin (2015) 0.83
CPEB1 promotes differentiation and suppresses EMT in mammary epithelial cells. J Cell Sci (2014) 0.83
Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget (2015) 0.82
SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia (2014) 0.82
Epigenetic regulation of a brain-specific glycosyltransferase N-acetylglucosaminyltransferase-IX (GnT-IX) by specific chromatin modifiers. J Biol Chem (2014) 0.82
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. Oncotarget (2015) 0.82
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun (2016) 0.81
Receptor-Independent Ectopic Activity of Prolactin Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies. Antioxid Redox Signal (2014) 0.81
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget (2014) 0.81
Decreased expression and aberrant methylation of Gadd45G is associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Clin Exp Metastasis (2013) 0.81
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer (2013) 0.80
DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers. Oncotarget (2015) 0.79
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin Pharmacol (2016) 0.78
Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol (2010) 0.78
Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma. PLoS One (2014) 0.78
Active chromatin marks are retained on X chromosomes lacking gene or repeat silencing despite XIST/Xist expression in somatic cell hybrids. PLoS One (2010) 0.77
Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis-associated cancer. J Cancer Res Clin Oncol (2015) 0.77
Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication. World J Gastroenterol (2012) 0.76
CPEB1 restrains proliferation of Glioblastoma cells through the regulation of p27(Kip1) mRNA translation. Sci Rep (2016) 0.75
Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma. PLoS One (2016) 0.75
Don't worry; be informed about the epigenetics of anxiety. Pharmacol Biochem Behav (2016) 0.75
JHDM3A module as an effector molecule in guide-directed modification of target chromatin. J Biol Chem (2010) 0.75
SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. Mol Cancer (2017) 0.75
Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia (2016) 0.75
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget (2015) 0.75
Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas. Oncotarget (2016) 0.75
An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol (2009) 7.93
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2008) 4.50
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab (2012) 2.36
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood (2008) 2.12
Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol (2003) 2.12
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol (2012) 2.09
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol (2013) 2.07
Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med (2013) 1.98
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res (2004) 1.97
Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res (2005) 1.93
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol (2007) 1.90
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood (2009) 1.84
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2009) 1.78
Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res (2002) 1.74
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol (2013) 1.70
Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J (2002) 1.66
Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology (2009) 1.64
Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol (2006) 1.63
The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo. Proc Natl Acad Sci U S A (2008) 1.62
Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species. FASEB J (2007) 1.60
Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation (2005) 1.60
Human but not mouse adipogenesis is critically dependent on LMO3. Cell Metab (2013) 1.57
Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood (2012) 1.56
Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer (2010) 1.50
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget (2012) 1.50
A mimic of sarcoidosis. Lancet (2007) 1.49
Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. Hepatology (2015) 1.49
Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res (2012) 1.46
Evidence for an association between mannose-binding lectin 2 (MBL2) gene polymorphisms and pre-term birth. Genet Med (2006) 1.44
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol (2007) 1.42
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma (2006) 1.42
Short-term rhythmic proliferation of human breast cancer cell lines: surface effects and fractal growth patterns. J Pathol (2002) 1.41
Activation of the canonical wingless/T-cell factor signaling pathway promotes invasive differentiation of human trophoblast. Am J Pathol (2006) 1.41
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood (2011) 1.40
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36
BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood (2012) 1.36
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat (2007) 1.35
Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst (2005) 1.34
Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene (2003) 1.33
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood (2004) 1.30
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica (2007) 1.30
Retracted DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res (2004) 1.26
Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol (2010) 1.25
Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res (2008) 1.25
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun (2009) 1.25
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica (2012) 1.25
Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev (2010) 1.24
Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol (2006) 1.21
Carbon monoxide protection against endotoxic shock involves reciprocal effects on iNOS in the lung and liver. FASEB J (2004) 1.19
Masked polycythemia vera (mPV): results of an international study. Am J Hematol (2013) 1.19
The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb Haemost (2009) 1.18
Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res (2004) 1.18
Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology (2010) 1.17
Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol (2004) 1.17
Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol (2006) 1.17
Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res (2006) 1.17
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res (2007) 1.16
Microarray-based identification of bacteria in clinical samples by solid-phase PCR amplification of 23S ribosomal DNA sequences. J Clin Microbiol (2004) 1.16
Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma. Am J Surg Pathol (2015) 1.16
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
NF-E2-related factor 2 regulates the stress response to UVA-1-oxidized phospholipids in skin cells. FASEB J (2009) 1.13
Kisspeptins and the placenta: regulation of trophoblast invasion. Rev Endocr Metab Disord (2007) 1.12
Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle (2007) 1.11
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer (2006) 1.09
Recurrent malignant Triton tumour: first report on a long time survivor. Oncol Rep (2003) 1.09
Deciphering regulatory patterns of inflammatory gene expression from interleukin-1-stimulated human endothelial cells. Arterioscler Thromb Vasc Biol (2004) 1.08
Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia (2005) 1.08
TLR 2 and CD14 mediate innate immunity and lung inflammation to staphylococcal Panton-Valentine leukocidin in vivo. J Immunol (2010) 1.07
A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica (2012) 1.07
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist (2011) 1.06
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer (2006) 1.05
The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat (2010) 1.05
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
The TLR-independent DNA recognition pathway in murine macrophages: Ligand features and molecular signature. Eur J Immunol (2009) 1.04
DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer (2004) 1.03
Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res (2005) 1.03
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol (2003) 1.03
Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum (2010) 1.03
B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C δ. Blood (2013) 1.02
Myeloid sarcoma with multiple lesions of the central nervous system in a patient without leukemia. Case report. J Neurosurg (2006) 1.01
A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther (2011) 1.01
Molecular pathogenesis of lung cancer and potential translational applications. Cancer J (2002) 1.00
Thromboembolic events during treatment with thalidomide. Blood (2002) 1.00
Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation (2010) 0.99
Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer (2007) 0.99